Related Experiment Videos
[Clinico-pathogenetic substantiation of the immunocorrective treatment of pyelonephritis in infants]
Insights
Immunomodulating drugs combined with antibiotics improved pyelonephritis treatment in infants. This therapy reduced disease duration, relapse rates, and antibiotic usage, leading to better immune recovery.
Area of Science:
- Pediatric Nephrology
- Immunology
- Pharmacology
Context:
- Pyelonephritis is a significant kidney infection in infants.
- Standard antimicrobial therapy can be limited by relapses and progression to chronic disease.
- Immunodeficiency is often observed in infants with severe or recurrent pyelonephritis.
Purpose:
- To evaluate the efficacy of immunomodulating drugs combined with antimicrobial therapy in treating infant pyelonephritis.
- To assess the impact of immunostimulation on disease course, relapse rates, and immunological parameters.
Summary:
- A study involved 47 infants with pyelonephritis treated with immunomodulators (t-activin, levamisole, sodium nucleinate, prodigiozan, lysozyme) and antimicrobials.
- Immunomodulators were indicated for immune deficiencies, unfavorable premorbid conditions, severe disease, or poor response to antibiotics.
- Compared to controls, immunostimulation therapy shortened the active phase of pyelonephritis, reduced relapses, and decreased the risk of chronicity.
Impact:
- Immunostimulation therapy significantly improved the clinical outcomes of pyelonephritis in infants.
- Combined treatment allowed for reduced duration, dosage, and frequency of antibiotic use.
- Successful pyelonephritis treatment led to the normalization of immunological parameters.
Abstract:
The results of the treatment of 47 babies treated with the immunocorrecting drugs (t-activin, levamisole, sodium nucleinate, prodigiozan, lysozyme) together with antimicrobial remedies are described. The babies were selected from 120 patients suffering from pyelonephritis. Indications for use of the immunomodulators included the deficiency of the T component of immunity, of phagocytosis and, more rarely, of B lymphocytes, an unfavourable premorbed condition, severe lingering disease course as well as low efficacy of antibacterial therapy. Two control groups consisted of 120 patients who were not given the immunocorrecting remedies and 30 normal children of the first year of life. The immunostimulation therapy minimized the duration of the active phase of pyelonephritis, decreasing the rate of relapses and the probability that the disease may progress to a chronic course. The positive influence of the above drugs on the clinical picture of pyelonephritis enabled the duration of antibacterial therapy, the dosage and the frequency of antibiotic use to be reduced. The favourable outcome of pyelonephritis was followed by gradual normalization of the immunological parameters.